The Daily Biotech Pulse: INmune Bio’s Planned Alzheimer’s Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours:
Ensysce Biosciences Announces Initiation Of First Human Abuse Potential Study
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and
Ensysce Biosciences Announces New Clinical Results From Trials PF614-102 And PF614-MPAR-101
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and
ENSC: Ensysce Releases Encouraging Financials
By Brad Sorensen, CFA
NASDAQ:ENSC
READ THE FULL ENSC RESEARCH REPORT
51 Biggest Movers From Yesterday
Gainers
Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell
• Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
42 Stocks Moving in Monday’s Pre-Market Session
Gainers
Nine Energy Service, Inc. (NYSE: NINE) rose 96.7% to $3.54 in pre-market trading after climbing around 43% on Friday. Shares of low-priced energy stocks jumped as crude surged to new highs.